NMDA antagonists and neuropathic pain - Multiple drug targets and multiple uses

Current Pharmaceutical Design

Volumn 11, Issue 23, 2005, Pages 2977-2994

  Chizh, Boris A ^a   Headley, P M ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Animal models; Glutamate receptors; GlycineB antagonists; Neuropathic pain; Nociception; RN2B antagonists

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; AMANTADINE; CALCIUM ION; DEXTROMETHORPHAN; DIZOCILPINE; GABAPENTIN; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; HALOPERIDOL; IFENPRODIL; KETAMINE; MAGNESIUM ION; MEMANTINE; MRZ 2576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NEUROPEPTIDE; PEPTIDE LIBRARY; POLYAMINE; PROTEIN SUBUNIT; PROTON; RECEPTOR SUBTYPE; RO 256921; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; HALLUCINATION; HEARING DISORDER; HUMAN; HYPERACTIVITY; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STEREOTYPY; TREATMENT OUTCOME; VISUAL DISORDER;

ANIMALS; CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 23844495851     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054865082     Document Type: Review

References (175)

1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
2. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.
3. Trist DG. Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications. Pharm Acta Helv 2000; 74: 221-9.
4. Chizh BA, Eide PK. Pain. In: Lodge D, Danysz W, Parsons CG Eds, Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and Modulators. Johnson City, F.P. Graham Publishing Co. 2002; 263-300.
5. Eide PK, Stubhaug A, Breivik H, Oye I. Reply to S.T. Meller: Ketamine: relief from chronic pain through actions at the NMDA receptor. Pain 1997; 72: 289-91.
6. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260: 1209-13.
7. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000; 91: 960-6.
8. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96: 1053-61.
9. Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998; 18: 2954-61.
10. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
11. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11: 327-35.
12. Sucher NJ, Akbarian S, Chi CL, Leclerc CL, Awobuluyi M, Deitcher DL, et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 1995; 15: 6509-20.
13. South SM, Kohno T, Kaspar BK, Hegarty D, Vissel B, Drake CT, et al. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 2003; 23: 5031-40.
14. Petrenko AB, Yamakura T, Baba H, Sakimura K. Unaltered pain-related behavior in mice lacking NMDA receptor GluRepsilon 1 subunit. Neurosci Res 2003; 46: 199-204.
15. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997; 18: 493-503.
16. Evans RH, Francis AA, Watkins JC. Selective antagonism by Mg2+ of amino acid-induced depolarization of spinal neurones. Experientia 1977; 33: 489-91.
17. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984; 307: 462-5.
18. Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des 2002; 8: 835-43.
19. Fletcher EJ, Millar JD, Zeman S, Lodge D. Non-Competitive Antagonism of N-Methyl-D-Aspartate by Displacement of an Endogenous Glycine-Like Substance. Eur J Neurosci 1989; 1: 196-203.
20. Salt TE. Modulation of NMDA receptor-mediated responses by glycine and D-serine in the rat thalamus in vivo. Brain Res 1989; 481: 403-6.
21. Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
22. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001; 22: 636-42.
23. Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 1995; 268: 873-6.
24. Caudle RM, Perez FM, King C, Yu CG, Yezierski RP. N-methyl-D-aspartate receptor subunit expression and phosphorylation following excitotoxic spinal cord injury in rats. Neurosci Lett 2003; 349: 37-40.
25. Guo W, Zou S, Guan Y, Ikeda T, Tal M, Dubner R, et al. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci 2002; 22: 6208-17.
26. Cumberbatch MJ, Chizh BA, Headley PM. Modulation of excitatory amino acid responses by tachykinins and selective tachykinin receptor agonists in the rat spinal cord. Br J Pharmacol 1995; 115: 1005-12.
27. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997; 386: 721-4.
28. Chizh BA, Headley PM. Thyrotropin-releasing hormone (TRH)-induced facilitation of spinal neurotransmission: a role for NMDA receptors. Neuropharmacology 1994; 33: 115-21.
29. Koenig ML, Yourick DL, Meyerhoff JL. Thyrotropin-releasing hormone (TRH) attenuates glutamate-stimulated increases in calcium in primary neuronal cultures. Brain Res 1996; 730: 143-9.
30. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75: 443-52.
31. Jeftinija S, Jeftinija K, Liu F, Skilling SR, Smullin DH, Larson AA. Excitatory amino acids are released from rat primary afferent neurons in vitro. Neurosci Lett 1991; 125: 191-4.
32. Kangrga i, Randic M. Outflow of endogenous aspartate and glutamate from the rat spinal dorsal horn in vitro by activation of low- and high-threshold primary afferent fibers. Modulation by mu-opioids. Brain Res 1991; 553: 347-52.
33. Teoh H, Malcangio M, Bowery NG. GABA, glutamate and substance P-like immunoreactivity release: effects of novel GABAB antagonists. Br J Pharmacol 1996; 118: 1153-60.
34. Cumberbatch MJ, Chizh BA, Headley PM. AMPA receptors have an equal role in spinal nociceptive and non- nociceptive transmission. Neuroreport 1994; 5: 877-80.
35. King AE, Lopez-Garcia JA. Excitatory amino acid receptor-mediated neurotransmission from cutaneous afferents in rat dorsal horn in vitro. J Physiol 1993; 472: 443-57.
36. Chizh BA, Cumberbatch MJ, Herrero JF, Stirk GC, Headley PM. Stimulus intensity, cell excitation and the N-methyl-D-aspartate receptor component of sensory responses in the rat spinal cord in vivo. Neuroscience 1997; 80: 251-65.
37. Cumberbatch MJ, Chizh BA, Headley PM. Spinal nociceptive processing: NMDA receptors and modulation by neuropeptides. In: Sirinathsinghji D, Hill RG Eds, NMDA Antagonists as Potential Analgesic Drugs. Base, Birkhäuser Verlag. 2002.
38. Dickenson A. Mechanisms of central hypersensitivity: excitatory amino acid mechanisms and their control. In: Dickenson A, Besson JM Eds, The Pharmacology of Pain. Berlin, Springer Verlag. 1997; 167-210.
39. Laird JM, Mason GS, Webb J, Hill RG, Hargreaves RJ. Effects of a partial agonist and a full antagonist acting at the glycine site of the NMDA receptor on inflammation-induced mechanical hyperalgesia in rats. Br J Pharmacol 1996; 117: 1487-92.
40. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990; 11: 307-9.
41. Ochoa J, Torebjork HE, Culp WJ, Schady W. Abnormal spontaneous activity in single sensory nerve fibers in humans. Muscle Nerve 1982; 5: S74-S77.
42. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259-85.
43. Urban L, Thompson SW, Dray A. Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci 1994; 17: 432-8.
44. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000; 4: 5-15.
45. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 2000; 61: 169-203.
46. Mendell LM. Physiological properties of unmyelinated fiber projection to the spinal cord. Exp Neurol 1966; 16: 316-32.
47. Arendt-Nielsen L, Petersen-Felix S. Wind-up and neuroplasticity: is there a correlation to clinical pain? Eur J Anaesthesiol Suppl 1995; 10: 1-7.
48. Chizh BA, Reissmuller E, Schlutz H, Scheede M, Haase G, Englberger W. Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil. Neuropharmacology 2001; 40: 212-20.
49. Price DD, Mao J, Frenk H, Mayer DJ. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 1994; 59: 165-74.
50. Chizh BA, Headley PM. Thyrotropin-releasing hormone facilitates spinal nociceptive responses by potentiating NMDA receptor-mediated transmission. Eur J Pharmacol 1996; 300: 183-9.
51. Sandkuhler J, Benrath J, Brechtel C, Ruscheweyh R, Heinke B. Synaptic mechanisms of hyperalgesia. Prog Brain Res 2000; 129: 81-100.
52. Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci 1995; 18: 54-6.
53. Sandkuhler J, Liu X. Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury. Eur J Neurosci 1998; 10: 2476-80.
54. Pockett S. Long-term potentiation and depression in the intermediate gray matter of rat spinal cord In vitro. Neuroscience 1995; 67: 791-8.
55. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003; 26: 696-705.
56. Burton AW, Lee DH, Saab C, Chung JM. Preemptive intrathecal ketamine injection produces a long-lasting decrease in neuropathic pain behaviors in a rat model. Reg Anesth Pain Med 1999; 24: 208-13.
57. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293-9.
58. Wallace MS, Ridgeway B, III, Leung A, Schulteis G, Yaksh TL. Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia. J Clin Pharmacol 2002; 42: 70-80.
59. Tverskoy M, Oz Y, Isakson A, Finger J, Bradley EL Jr, Kissin I. Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia. Anesth Analg 1994; 78: 205-9.
60. Fu ES, Miguel R, Scharf JE. Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery. Anesth Analg 1997; 84: 1086-90.
61. Mathisen LC, Aasbo V, Raeder J. Lack of pre-emptive analgesic effect of (R)-ketamine in laparoscopic cholecystectomy. Acta Anaesthesiol Scand 1999; 43: 220-4.
62. Jaksch W, Lang S, Reichhalter R, Raab G, Dann K, Fitzal S. Perioperative small-dose S(+)-ketamine has no incremental beneficial effects on postoperative pain when standard-practice opioid infusions are used. Anesth Analg 2002; 94: 981-6.
63. Aida S, Yamakura T, Baba H, Taga K, Fukuda S, Shimoji K. Preemptive analgesia by intravenous low-dose ketamine and epidural morphine in gastrectomy: a randomized double-blind study. Anesthesiology 2000; 92: 1624-30.
64. Park KM, Max MB, Robinovitz E, Gracely RH, Bennett GJ. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain 1995; 63: 163-72.
65. Gottrup H, Hansen PO, Arendt-Nielsen L, Jensen TS. Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans. Br J Anaesth 2000; 84: 155-62.
66. Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001; 95: 395-402.
67. Warncke T, Stubhaug A, Jorum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 1997; 72: 99-106.
68. Wallace MS, Braun J, Schulteis G. Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin-induced pain and hyperalgesia. Clin J Pain 2002; 18: 373-9.
69. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998; 5: 209-27.
70. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain 2000; 88: 125-33.
71. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995; 37: 1080-7.
72. Eisenberg E, Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain 1998; 74: 337-9.
73. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998; 75: 349-54.
74. Chizh BA, Englberger W, Parsons CG, Christoph T. The antiallodynic effect of N-methyl-D-aspartate (NMDA) antagonists in neuropathic pain outlasts the block of NMDA receptors. Soc Neurosci Abstr 2001; 27: 53.14.
75. Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 1999; 289: 1060-6.
76. Carlton SM, Hargett GL, Coggeshall RE. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. Neurosci Lett 1995; 197: 25-8.
77. Lawand NB, Willis WD, Westlund KN. Excitatory amino acid receptor involvement in peripheral nociceptive transmission in rats. Eur J Pharmacol 1997; 324: 169-77.
78. Zhou S, Bonasera L, Carlton SM. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport 1996; 7: 895-900.
79. Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res 1999; 820: 63-70.
80. Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, Galer BS, et al. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002; 59: 1694-700.
81. Gaunitz C, Schuttler A, Gillen C, Allgaier C. Formalin-induced changes of NMDA receptor subunit expression in the spinal cord of the rat. Amino Acids 2002; 23: 177-82.
82. Karlsson U, Sjodin J, Angeby MK, Johansson S, Wikstrom L, Nasstrom J. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation. Neuroscience 2002; 112: 861-8.
83. Sundstrom E, Whittemore S, Mo LL, Seiger A. Analysis of NMDA receptors in the human spinal cord. Exp Neurol 1997; 148: 407-13.
84. Tolle TR, Berthele A, Zieglgansberger W, Seeburg PH, Wisden W. The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray. J Neurosci 1993; 13: 5009-28.
85. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38: 611-23.
86. Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 2000; 101: 699-707.
87. Luque JM, Bleuel Z, Malherbe P, Richards JG. Alternatively spliced isoforms of the N-methyl-D-aspartate receptor subunit 1 are differentially distributed within the rat spinal cord. Neuroscience 1994; 63: 629-35.
88. Watanabe M, Mishina M, Inoue Y. Distinct distributions of five NMDA receptor channel subunit mRNAs in the brainstem. J Comp Neurol 1994; 343: 520-31.
89. Miki K, Zhou QQ, Guo W, Guan Y, Terayama R, Dubner I, et al. Changes in gene expression and neuronal phenotype in brain stem pain modulatory circuitry after inflammation. J Neurophysiol 2002; 87: 750-60.
90. Ibrahim HM, Healy DJ, Hogg AJ, Jr., Meador-Woodruff JH. Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus. Brain Res Mol Brain Res 2000; 79: 1-17.
91. Wenzel A, Scheurer L, Kunzi R, Fritschy JM, Mohler H, Benke D. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. Neuroreport 1995; 7: 45-8.
92. Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, et al. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci 2001; 4: 164-9.
93. Evans RH. Evidence supporting the indirect depolarization of primary afferent terminals in the frog by excitatory amino acids. J Physiol 1980; 298: 25-35.
94. Coggeshall RE, Carlton SM. Receptor localization in the mammalian dorsal horn and primary afferent neurons. Brain Res Brain Res Rev 1997; 24: 28-66.
95. McRoberts JA, Coutinho SV, Marvizon JC, Grady EF, Tognetto M, Sengupta JN, et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001; 120: 1737-48.
96. Marvizon JC, McRoberts JA, Ennes HS, Song B, Wang X, Jinton L, et al. Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with different subunit composition and localization. J Comp Neurol 2002; 446: 325-41.
97. Carlton SM, Chung K, Ding Z, Coggeshall RE. Glutamate receptors on postganglionic sympathetic axons. Neuroscience 1998; 83: 601-5.
98. Coggeshall RE, Carlton SM. Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferents. Pain 1999; 83: 163-8.
99. Cincotta M, Beart PM, Summers RJ, Lodge D. Bidirectional transport of NMDA receptor and ionophore in the vagus nerve. Eur J Pharmacol 1989; 160: 167-71.
100. Harmar A, Keen P. Synthesis, and central and peripheral axonal transport of substance P in a dorsal root ganglion-nerve preparation in vitro. Brain Res 1982; 231: 379-85.
101. Carlton SM. Peripheral excitatory amino acids. Curr Opin Pharmacol 2001; 1: 52-6.
102. Kristensen JD, Svensson B, Gordh T, Jr. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992; 51: 249-53.
103. Donevan SD, McCabe RT. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 2000; 58: 614-23.
104. Klein RC, Prorok M, Galdzicki Z, Castellino FJ. The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors. J Biol Chem 2001; 276: 26860-7.
105. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-75.
106. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development - an update. Drug News Perspect 1998; 11: 523-69.
107. Kew JN, Trube G, Kemp JA. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 1996; 497 ( Pt 3): 761-72.
108. Kew JN, Kemp JA. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 1998; 512 (Pt 1): 17-28.
109. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1998; 1: 659-67.
110. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000; 20: 358-73.
111. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. Drug News Perspect 1995; 8: 261-77.
112. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999; 38: 735-67.
113. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12: 4427-36.
114. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993; 32: 1337-50.
115. Jones MW, McClean M, Parsons CG, Headley PM. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones. Neuropharmacology 2001; 41: 50-61.
116. Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain 2001; 91: 101-9.
117. Eisenberg E, LaCross S, Strassman AM. The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett 1995; 187: 17-20.
118. Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998; 2: 321-7.
119. Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain 2003; 103: 277-83.
120. Schepelmann K, Schugens MM, Loschmann PA, Klockgether T, Dichgans J. The non-competitive N-methyl-D-aspartate-antagonist memantine does not affect segmental mono- and polysynaptic reflexes in man. Neurosci Lett 1998; 257: 159-61.
121. B antagonists: evidence for a peripheral mechanism. Soc Neurosci Abstr 2000; 26: 356.2.
122. McClean M, Chizh BA, Headley PM. Effects of NMDA receptor antagonists on nociceptive responses in vivo: comparison of antagonists acting at the glycine site with uncompetitive antagonists. Amino Acids 1998; 14: 217-21.
123. Davidson EM, Coggeshall RE, Carlton SM. Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formal in test. Neuroreport 1997; 8: 941-6.
124. Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001; 91: 177-87.
125. deGroot J, Zhou S, Carlton SM. Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. Neuroreport 2000; 11: 497-502.
126. Lawand NB, McNearney T, Westlund KN. Amino acid release into the knee joint: key role in nociception and inflammation. Pain 2000; 86: 69-74.
127. Quartaroli M, Carignani C, Dal Forno G, Mugnaini M, Ugolini A, Arban R, et al. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. J Pharmacol Exp Ther 1999; 290: 158-69.
128. Bordi F, Quartaroli M. Modulation of nociceptive transmission by NMDA/glycine site receptor in the ventroposterolateral nucleus of the thalamus. Pain 2000; 84: 213-24.
129. Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 1999; 5: 381-404.
130. Farkas S, Horvath C, Nagy J, Kolok S, Fodor L, Gere A, et al. RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Soc Neurosci Abstr 2003;382.8.
131. Bernardi M, Bertolini A, Szczawinska K, Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Eur J Pharmacol 1996; 298: 51-5.
132. Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS, et al. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 1997; 122: 809-12.
133. Carter RB, Wilent W, Huber M, Xu Z, Vanover KE, Woodward RM. Anti-allodynic and anti-hyperalgesic effects of the NR2B subunit-selective NMDA antagonist CI-1041 in rat models of inflammation and neuropathy. Soc Neurosci Abstr 2000; 26: 617.3.
134. Fillhard JA, Kinsora JJ, Meltzer LT. The effects of CI-1041 in two tests of analgesia: acetic acid-induced writhing test and formalin foot pad test. Soc Neurosci Abstr 2000; 26: 617.4.
135. Sang CN, Weaver JJ, Jinga L, Wouden J, Saltarelli MD. The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Soc Neurosci Abstr 2003;814.9.
136. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994; 12: 529-40.
137. Momiyama A. Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord. J Physiol 2000; 523: 621-8.
138. Kovacs G, Kocsis P, Tarnawa I, Horvath C, Szombathelyi Z, Farkas S. NR2B containing NMDA receptor dependent windup of single spinal neurons. Neuropharmacology 2004; 46: 23-30.
139. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. Genetic enhancement of learning and memory in mice. Nature 1999; 401: 63-9.
140. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429: 71-8.
141. Witchel HJ, Hancox JC. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000; 27: 753-66.
142. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999; 5: 1396-402.
143. Chen SR, Wozniak KM, Slusher BS, Pan HL. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 2002; 300: 662-7.
144. Yamamoto T, Yaksh TL. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 1992; 135: 67-70.
145. Chizh BA, Schlutz H, Scheede M, Englberger W. The N-methyl-D-aspartate antagonistic and opioid components of d- methadone antinociception in the rat spinal cord. Neurosci Lett 2000; 296: 117-20.
146. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol 1998; 56: 553-9.
147. Popik P, Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 1996; 53: 791-7.
148. Houghton AK, Parsons CG, Headley PM. Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain 2001; 91: 201-7.
149. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259-74.
150. Ueda H, Inoue M, Mizuno K. New approaches to study the development of morphine tolerance and dependence. Life Sci 2003; 74: 313-20.
151. Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 1996; 43: 379-83.
152. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001; 21: 338-54.
153. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Research 1998; 29: 233-49.
154. Calabresi P, Centonze D, Marfia GA, Pisani A, Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br J Pharmacol 1999; 126: 689-96.
155. Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000; 130: 900-6.
156. Chizh BA, Scheede M, Schlutz H. Antinociception and (R,S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid antagonism by gabapentin in the rat spinal cord in vivo. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 197-200.
157. Gu Y, Huang LY. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neurosci Lett 2002; 324: 177-80.
158. Moore KA, Baba H, Woolf CJ. Gabapentin- actions on adult superficial dorsal horn neurons. Neuropharmacology 2002; 43: 1077-81.
159. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46.
160. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58: 347-54.
161. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995; 18: 360-8.
162. Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1996; 64: 283-91.
163. Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996; 67: 69-77.
164. McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994; 59: 127-33.
165. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212-8.
166. Kawamata T, Omote K, Sonoda H, Kawamata M, Namiki A. Analgesic mechanisms of ketamine in the presence and absence of peripheral inflammation. Anesthesiology 2000; 93: 520-8.
167. Qian J, Brown SD, Carlton SM. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res 1996; 715: 51-62.
168. Olivar T, Laird JM. Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 1999; 79: 67-73.
169. Danysz W, Essmann U, Bresink I, Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994; 48: 111-8.
170. Kozlowski CM, Bountra C, Grundy D. The effect of fentanyl, DNQX and MK-801 on dorsal horn neurones responsive to colorectal distension in the anaesthetized rat. Neurogastroenterol Motil 2000; 12: 239-47.
171. Murray F, Kennedy J, Hutson PH, Elliot J, Huscroft I, Mohnen K, et al. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 2000; 397: 263-70.
172. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, et al. Novel systemically active antagonists of the glycine site of the N- methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997; 283: 1264-75.
173. Berenguer B, La Casa C, de la Matta MJ, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Design 2004; 10(31): 3931-46.
174. Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Curr Pharm Design 2004; 10(3): 253-9.
175. Sabatowski R, Schafer D, Kasper SM, Brunsch H, Radbruch L. Pain treatment: a historical overview. Curr Pharm Design 2004; 10(7): 701-16.